Analyst Yun Zhong from Wedbush maintained a Buy rating on MannKind and keeping the price target at $11.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yun Zhong has given his Buy rating due to a combination of factors related to MannKind’s strategic acquisition and growth prospects. The acquisition of scPharmaceuticals is expected to diversify MannKind’s product portfolio and enhance its presence in the cardiorenal space, which targets a large patient population. This move is anticipated to be accretive to earnings by the second half of 2026, leveraging MannKind’s existing expertise in drug-device combinations and expanding its market reach.
Additionally, the acquisition aligns with MannKind’s strategic goals by providing synergy with its current portfolio, particularly with the potential growth of Furoscix, a product with increasing adoption in cardiology and nephrology. The planned introduction of an autoinjector is expected to further improve patient adoption by reducing costs and treatment time. Furthermore, MannKind’s ongoing developments in its orphan lung programs and Afrezza, combined with strategic financing agreements, position the company for significant growth and potential market expansion.
Zhong covers the Healthcare sector, focusing on stocks such as MannKind, Ascendis Pharma, and Rocket Pharmaceuticals. According to TipRanks, Zhong has an average return of -12.7% and a 42.15% success rate on recommended stocks.